- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 3- How Payers Will Access the Value of New Agents
Dr Weber said that despite all of the newer agents in development, the NCCN still offers comprehensive guidelines for the treatment of melanoma.
Dr Weber said that despite all of the newer agents in development, the NCCN still offers comprehensive guidelines for the treatment of melanoma.
“There’s so much innovation and so many exciting new therapies that there aren’t hard data on how to sequence them, and so you really have to rely on experts to provide that kind of guidance to people out there in the community treating patients,” said Dr Malin.
Dr Malin also noted her concerns with the costs of newer agents. She explained that the majority of small independent practices will be concerned about prescribing expensive medications when they do not know what the patient’s insurance will cover, or if the patient can pay their copay.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Margin Status Likely Not a Factor in STS Recurrence
May 10th 2024The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More
